Shortcuts 2023 2022 2021 2020 2019
2023
-
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
-
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
-
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
-
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
-
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
-
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
2022
-
BioCardia Announces $3.6 Million Private Placement of Common Stock
-
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
-
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
-
BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines Conference
-
BioCardia Reports Second Quarter 2022 Business Highlights and Financial Results
-
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
-
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial
-
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia
-
BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
-
BioCardia Reports First Quarter 2022 Business Highlights and Financial Results
-
BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022
-
BioCardia Reports 2021 Financial Results and Recent Business Highlights
-
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
2021
-
BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
-
BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
-
BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
-
BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
-
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
-
BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
-
BioCardia to Present at the LD Micro Virtual Invitational Conference on June 8, 2021
-
BioCardia Reports First Quarter 2021 Financial Results and Business Highlights
-
BioCardia Reports 2020 Financial Results and Recent Business Highlights
-
BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
-
BioCardia Update on Cell Therapy Product Development and 2021
-
Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors
2020
-
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies
-
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights
-
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
-
BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020
-
BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights
-
BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020
-
BioCardia Announces Pricing of $10.0 Million Public Offering
-
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
-
BioCardia Reports 2019 Financial Results and Recent Business Highlights
-
BioCardia Announces FDA Clearance of Morph DNA Deflectable Guide Catheter
2019
-
BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights
-
BioCardia to Present at Dawson James Securities' 5th Annual Small Cap Growth Conference
-
BioCardia Announces the Appointment of Two New Board Members
-
BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights
-
BioCardia Announces Closing of $10.0 Million Public Offering
-
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to NASDAQ
-
BioCardia Signs Exclusive Development Agreement with AstraZeneca
-
BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery
-
BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange
-
Biocardia Reports 2019 First Quarter Financial Results and Business Highlights
-
BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transeptal Access to Heart
-
BioCardia Reports 2018 Financial Results and Recent Business Highlights
News

Fierce Biotech

Empowered Patient Podcast

UW Health

Greenbay CBS


Henry Ford Health System
press releases
CALL US NOW
EMAIL US NOW